The
RNA-specific
cytidine deaminase apobec-1 is an AU-rich
RNA binding protein that binds the
3' untranslated region (UTR) of
cyclooxygenase-2 (Cox-2)
mRNA and stabilizes its turnover in vitro. Cox-2 overexpression accompanies intestinal
adenoma formation in both humans and mice. Evidence from both genetic deletion studies as well as from pharmacologic inhibition has implicated Cox-2 in the development of intestinal
adenomas in experimental animals and in
adenomas and
colorectal cancer in humans. Here, we show that small intestinal
adenoma formation is dramatically reduced in compound Apc(min/+) apobec-1(-/-) mice when compared with the parental Apc(min/+) strain. This reduced
tumor burden was found in association with increased small intestinal apoptosis and reduced proliferation in small intestinal crypt-villus units from compound Apc(min/+) apobec-1(-/-) mice. Intestinal
adenomas from compound Apc(min/+) apobec-1(-/-) mice showed a <2-fold increase in Cox-2
mRNA abundance and reduced
prostaglandin E(2) content compared with
adenomas from the parental Apc(min/+) strain. In addition, there was reduced expression in
adenomas from compound Apc(min/+) apobec-1(-/-) mice of other mRNAs (including
epidermal growth factor receptor,
peroxisome proliferator-activated receptor delta,
prostaglandin receptor EP4, and c-myc), each containing the
apobec-1 consensus binding site within their 3'-UTR. Adenovirus-mediated
apobec-1 introduction into HCA-7 (
colorectal cancer) cells showed a dose-dependent increase in Cox-2
protein and stabilization of endogenous Cox-2
mRNA. These findings suggest that deletion of
apobec-1, by modulating expression of AU-rich
RNA targets, provides an important mechanism for attenuating a dominant genetic restriction point in intestinal
adenoma formation.